Fox Chase Cancer Center News

PHILADELPHIA, PA (August 9, 2013)—Vasily Studitsky, PhD, has joined Fox Chase Cancer Center as a Professor in the Cancer Epigenetics Program. He comes to Fox Chase from Wayne State University and the University of Medicine and Dentistry of New Jersey, where he was a full Professor. Dr. Studitsky’s research looks at molecular mechanisms and regulation of eukaryotic transcription, and the factors involved in cancer development and human aging.

PHILADELPHIA, PA (July 29, 2013)—Richard I. Fisher, MD, a leading cancer center administrator and nationally recognized hematology/oncology expert who joined Temple Health on March 1, 2013, has been appointed President and CEO of Fox Chase Cancer Center.

PHILADELPHIA, PA (July 25, 2013)—Daniel M. Geynisman, MD, has joined Fox Chase’s department of medical oncology after completing a hematology/oncology fellowship at the University of Chicago Medical Center, where he served as chief fellow in his final year. While there, he completed an additional fellowship at the MacLean Center for Clinical Medical Ethics. He specializes in treating patients with genitourinary cancers, including prostate, bladder, kidney, testicular, penile, and adrenal cancers.

PHILADELPHIA, PA (July 25, 2013)—Gina M. Mantia-Smaldone, MD, has joined Fox Chase Cancer Center as a gynecologic oncology surgeon after completing fellowship training in the division of gynecologic oncology at the Hospital of the University of Pennsylvania. She specializes in treating patients with ovarian cancer and other gynecologic cancers.

PHILADELPHIA (July 16, 2013)—Once again, Fox Chase Cancer Center has been ranked among the best hospitals in the nation for cancer care by U.S. News & World Report. In the just-released 2013-14 rankings, Fox Chase is ranked 30th in the nation in the specialty of cancer care.

PHILADELPHIA, PA (July 15, 2013)—Results from the Fox Chase study could eventually lead to the first treatment for autosomal dominant polycystic kidney disease (ADPKD)—a life-threatening and debilitating condition, and the most common inherited kidney disease.  A new compound reduces the symptoms of ADPKD in a mouse model, according to research from Fox Chase Cancer Center that will appear in the July 15, 2013 issue of the Proceedings of the National Academy of Sciences.

ROCKLEDGE, PA (July 20, 2013)—The Creative Beginnings early childhood program, which has been serving the childcare needs of Fox Chase Cancer Center employees for more than thirty years, is opening enrollment to members of the public. For the first time, community members will have the opportunity to take advantage of the high-quality program, which is accredited by the National Association for the Education of Young Children (NAEYC) and rated STAR 4 by 

CHICAGO, IL (May 29, 2013)—Monoclonal antibodies represent a promising treatment strategy for a range of cancers because they harness the immune system to specifically target and kill cancer cells while sparing normal cells, thereby reducing harmful side effects. Many monoclonal antibodies have been approved by the Food and Drug Administration (FDA), and in combination with standard chemotherapy or radiotherapy regimens, they can help to prevent tumor growth and metastasis and prolong patient survival.